BL-001 is under clinical development by Bloom Science and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BL-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BL-001 overview
BL-001 is under development for the treatment of epilepsy, Dravet Syndrome and amyotrophic lateral sclerosis. The drug comprises live bacteria from microbiome and administered through oral route.
Bloom Science overview
Bloom Science operates as a biotechnology company that focuses to discover and develop neuroprotective medicines for epilepsy and other neurological conditions. The company specializes in developing microbiota-based therapeutics to treat rare epilepsy syndromes and enhance brain health. Bloom Science aims to identify microbes with therapeutic potential by hacking the ketogenic diet, and develop those microbes as neuroprotective therapies. The company is also developing a medical food product which uses GRAS (generally regarded as safe) designation to provide safety and empower the company to transition directly into a proof-of-concept trial in patients. Bloom Science is headquartered in San Diego, California, the US.
For a complete picture of BL-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
